ClinicalTrials.gg
CompletedNCT07329972Updated May 11, 2026

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

A Phase 1 interventional study of ZN-A-1041 Formulation 1 and ZN-A-1041 Formulation 2 in Healthy Volunteers, sponsored by Genentech, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) within the range of 18 to 32 kg/m2, inclusive
  • In good health, determined by no findings from medical history, physical examination, 12-lead , and vital signs, as determined by the investigator, at Screening and Check-in, as applicable
  • Clinical laboratory evaluations (including chemistry panel, CBC, and UA with complete microscopic analysis) within the normal reference ranges for the certified test laboratory at Screening and Check-in
  • Negative test for selected drugs of abuse at Screening and Check-in (includes alcohol)
  • Negative hepatitis panel ( surface antigen, hepatitis B core antibody, hepatitis B surface antibody [unless consistent with vaccination or immunity due to natural infection], and virus antibody) and negative antibody screens
  • For women of : agreement to remain abstinent or use
  • For men: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating sperm
  • Negative screening test for latent Mycobacterium tuberculosis infection
  • Able to swallow and retain multiple tablets without chewing or crushing
  • Able to consume the high-fat meal within the protocol-specified time period and willing to consume 100% of the high-fat meal
  • Able to fast for 8 hours prior to dosing

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder, as determined by the investigator
  • History or concurrent hemorrhagic, bleeding abnormalities, as determined by the investigator
  • Personal or family history of congenital long syndrome
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
  • History of GI surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that uncomplicated appendectomy and hernia repair will be allowed
  • History of myocardial infarction
  • History of febrile illness within 10 days prior to the first dose of study drug, or participants with evidence of active systemic infection, as determined by the investigator
  • History of acute GI symptoms (e.g., nausea, vomiting, diarrhea, heartburn) as determined by the investigator (or designee) at Screening or Check-in
  • History of ophthalmological disease or clinically significant abnormality in the ophthalmic examination as determined by the investigator, optometrist, or ophthalmologist
  • Risk for suicidal behavior at Screening as determined by the investigator's clinical assessment and an answer "Yes" to item 4 or 5 within 2 years of Screening, or to suicidal behavior items on the Baseline/Screening version C-SSRS or suicide attempt within 2 years of screening. Non-suicidal self-injurious behavior is not exclusionary.
  • Have significantly impaired hepatic function (at Screening or Check-in)
  • Female who is pregnant or breastfeeding or intending to become pregnant during the study or within 90 days following the final ZN-A-1041 administration
  • Have a corrected QT (QTc) interval corrected through use of Fredericia's formula >450 msec for males or >470 for females, PR interval >210 msec, QRS complex >120 msec, or heart rate \<50 bpm (at Screening or Check-in)
  • History or presence of an abnormal that, in the investigator's opinion, is clinically significant, such as symptomatic bradyarrhythmias, bradycardia, or heart block as determined from 12-lead ECG (at Screening, Check-in, or Day 1 predose). Abnormal results can be confirmed by one repeat 12-lead ECG
  • History of alcoholism or drug addiction within 1 year prior to Check-in, use of drugs of abuse (including opioids) within 4 weeks of Screening, and/or positive alcohol breath test and/or urinary drug screen at Screening or Check-in
  • Participation in any other study drug trial in which receipt of an investigational study drug occurred within 5 half-lives or 90 days, whichever is longer, prior to Check-in
  • Treatment with intravenous (IV) antibiotics within 8 weeks prior to Screening and/or treatment with oral antibiotics within 4 weeks prior to Screening
  • Use of any drugs known to be moderate or strong inhibitors or inducers of or CYP2C8 within 30 days prior to Check-in
  • Use of any other prescription medications/products or vaccines (including seasonal flu, H1N1, and coronavirus 2019 [COVID-19] vaccines) other than oral, implantable, transdermal, and injectable or medications administered during the ophthalmic examination within 14 days prior to Check-in, unless deemed acceptable by the investigator
  • Use of therapeutic anticoagulation or thrombolytic anticoagulants within 14 days prior to Check-in
  • Use of any over-the-counter, non-prescription medications (including vitamins; minerals; and phytotherapeutic-, herbal-, and plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the investigator
  • Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 3 months prior to Check-in or a positive cotinine test
  • Use of poppy seed-, grapefruit-, star fruit-, pomegranate-, pawpaw-, or Seville orange-containing foods or beverages within 7 days prior to Check-in
  • Use of alcohol- or caffeine-containing foods or beverages within 48 hours prior to Check-in, unless deemed acceptable by the investigator
  • Participant is not willing to minimize or avoid exposure to natural or artificial sunlight (tanning beds or ultraviolet (UV) A/B treatment) following administration of study drug through 5 days following the final ZN-A-1041 administration
  • Participant is not willing to refrain from strenuous exercise from 7 days prior to Check-in and during the period of confinement at the study site (e.g., will not begin a new exercise program or participate in any unusually strenuous physical exertion)
  • Poor peripheral venous access as determined by the investigator
  • History of within 5 years prior to enrollment, with the exception of those with a negligible risk of or death (such as adequately treated carcinoma in situ of the cervix or basal cell skin cancer)
  • Donation of blood within 3 months prior to Screening through study completion, donation of plasma within 2 weeks prior to Screening through study completion, or donation of within 6 weeks prior to Screening through study completion
  • Receipt of blood products within 2 months prior to Screening and during the entire study duration
  • Participants who, in the opinion of the investigator (or designee), should not participate in this clinical study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Drug: ZN-A-1041 Formulation 1 · Drug: Rabeprazole

  • Experimental
    Sequence 2

    Drug: ZN-A-1041 Formulation 1 · Drug: Rabeprazole

  • Experimental
    Sequence 3

    Drug: ZN-A-1041 Formulation 1 · Drug: Rabeprazole

  • Experimental
    Sequence 4

    Drug: ZN-A-1041 Formulation 1 · Drug: Rabeprazole

  • Experimental
    Sequence 5

    Drug: ZN-A-1041 Formulation 2 · Drug: Rabeprazole

  • Experimental
    Sequence 6

    Drug: ZN-A-1041 Formulation 2 · Drug: Rabeprazole

  • Experimental
    Sequence 7

    Drug: ZN-A-1041 Formulation 2 · Drug: Rabeprazole

  • Experimental
    Sequence 8

    Drug: ZN-A-1041 Formulation 2 · Drug: Rabeprazole

Interventions

  • DrugZN-A-1041 Formulation 1

    Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

  • DrugZN-A-1041 Formulation 2

    Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

  • DrugRabeprazole

    Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax)

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  2. Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t)

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  3. AUC Extrapolated to Infinity (AUC0-∞)

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  4. Geometric Mean Ratio and Associated 90% Confidence Interval (CI) of Cmax, AUC0-t, and AUC0-∞

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

Secondary outcomes

  1. ZN-A-1041 PK Parameters Time to Maximum Observed Concentration (Tmax) for All Treatments

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  2. ZN-A-1041 Apparent Terminal Elimination Rate Constant (λz) for All Treatments

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  3. ZN-A-1041 Apparent Terminal Elimination Half-life (t1/2) for All Treatments

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  4. ZN-A-1041 Apparent Systemic Clearance (CL/F) for All Treatments

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  5. ZN-A-1041 Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) for All Treatments

    Time frame: Days 1 to 8, 11 to 14, and 17 to 20

  6. Incidence of Adverse Events (AEs), Including Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

    Time frame: Up to approximately 8.5 weeks

  7. Severity of AEs, Including SAEs and AESIs

    Time frame: Up to approximately 8.5 weeks

  8. Number of Participants with Abnormalities in Clinical Laboratory Results

    Time frame: Baseline, Days 2, 4, 6, 10, 16, and 20

  9. Changes from Baseline in Oral Temperature Measurements

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  10. Columbia Suicide Severity Rating Scale (C-SSRS) Questionnaires

    Time frame: Baseline, Day 1, 5, 11, 17, and 20

  11. Changes from Baseline in Respiratory Rate Measurements

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  12. Changes from Baseline in Systolic Blood Pressure Measurements

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  13. Changes from Baseline in Pulse Rate Measurements

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  14. Changes from Baseline in Diastolic Blood Pressure Measurements

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  15. Changes from Baseline in 12-lead Electrocardiogram (ECG) Parameters (RR, PR, QRS, and QT Duration)

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  16. Changes from Baseline in 12-lead ECG Parameters (Heart Rate)

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  17. Changes from Baseline in 12-lead ECG Parameters (Sinus Rhythm)

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

  18. Changes from Baseline in 12-lead ECG Parameters (QTcF)

    Time frame: Baseline, Days 1, 2, 5, 6, 11, 12, 17, 18, and 20

07

Study locations

2 sites
  • Daytona Beach Clinical Rsch Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247-4989, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Dec 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Jan 9, 2026
StartActual
Nov 21, 2025
Primary completionActual
Dec 14, 2025
CompletionActual
Dec 14, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329972
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Nov 21, 2025
Primary completion
Dec 14, 2025
Completion
Dec 14, 2025
Last update
May 11, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion